Clinical Trial Update: Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the Bruton tyrosine kinase inhibitor zanubrutinib in CD79B-mutant relapsed/refractory diffuse large B-cell lymphoma; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2026-03-25